Home » CEPTOR SECURES $20.0 MILLION EQUITY COMMITMENT FROM FUSION CAPITAL
CEPTOR SECURES $20.0 MILLION EQUITY COMMITMENT FROM FUSION CAPITAL
CepTor Corporation, Inc., a development-stage biopharmaceutical company focusing
on cell targeted therapeutic products for neuromuscular and neurodegenerative
diseases, announced it has entered into a common stock purchase agreement with
Fusion Capital Fund II, LLC, a Chicago based institutional investor, whereby
Fusion Capital has agreed to purchase up to $20.0 million of common stock. A
more detailed description of the transaction is set forth in the Company's report
on Form 8-K, recently filed with the SEC.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May